港股異動 | 麗珠醫藥(1513.HK)放量升超6% 注射用艾普拉唑鈉繼續納入醫保目錄
格隆匯12月6日丨麗珠醫藥(1513.HK)午後持續拉昇,現漲6.24%,報26.45港元,成交額放大至9111萬港元,總市值248億港元。公司重點產品注射用艾普拉唑鈉日前通過談判續約,繼續納入國家醫保目錄,適應症為消化性潰瘍出血。此次續談結果取消了原報銷範圍中“禁食醫囑或吞嚥困難”的限制,使得適用性更廣。據悉,新版醫保目錄於2022年1月1日起正式執行。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.